Foundation Medicine Announces Partnership with Repare Therapeutics to Provide Genomic Profiling Services to Support Clinical Trials and to Develop Companion Diagnostic for Lunresertib [Yah...
Repare Therapeutics Inc. - Common Shares (RPTX)
Company Research
Source: Yahoo! Finance
leading clinical-stage precision oncology company, to provide prospective genomic profiling to patients in Repare's ongoing Phase I/Ib MYTHIC study ( NCT04855656 ) of lunresertib alone or in combinations in genomically-defined patient populations. The companies are also exploring opportunities to develop FoundationOne ® CDx, a tissue-based comprehensive genomic profiling test, as a companion diagnostic for the lunresertib program. Lunresertib is a first-in-class, selective and potent oral small molecule inhibitor of PKMYT1, a cancer target Repare discovered and identified as synthetic lethal with CCNE1 amplification, FBXW7 and PPP2R1A alterations in solid tumors. Lunresertib is being evaluated alone and in combinations across several studies in the United States, Canada, European Union and United Kingdom. Repare has presented positive initial Phase 1 data, including compelling safety and anti-tumor activity, demonstrating proof of concept for lunresertib alone and in combination wit
Show less
Read more
Impact Snapshot
Event Time:
RPTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RPTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RPTX alerts
High impacting Repare Therapeutics Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
RPTX
News
- Repare Therapeutics Announces Positive Initial Data at ESMO GI from Phase 1 MINOTAUR Trial Evaluating Lunresertib in Combination with FOLFIRI [Yahoo! Finance]Yahoo! Finance
- Repare Therapeutics Announces Positive Initial Data at ESMO GI from Phase 1 MINOTAUR Trial Evaluating Lunresertib in Combination with FOLFIRIBusiness Wire
- Remix Therapeutics™ Appoints Maria Koehler, M.D., Ph.D., as an Independent Board Director [Yahoo! Finance]Yahoo! Finance
- Repare Therapeutics Doses First Patient in Camonsertib Monotherapy Non-Small Cell Lung Cancer Expansion of TRESR Clinical Trial [Yahoo! Finance]Yahoo! Finance
- Repare Therapeutics Doses First Patient in Camonsertib Monotherapy Non-Small Cell Lung Cancer Expansion of TRESR Clinical TrialBusiness Wire
RPTX
Earnings
- 2/28/24 - Miss
RPTX
Sec Filings
- 6/20/24 - Form 4
- 6/20/24 - Form 4
- 6/20/24 - Form 4
- RPTX's page on the SEC website